EUCTR2017-003257-42-GB进行中（未招募）1 期
Repeat-Dose Pharmacokinetic and Pharmacodynamic Evaluation of Cytisine in Healthy Smokers - Repeat-Dose PK and PD Evaluation of Cytisine in Healthy Smokers
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 26
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •To be Confirmed at Screening
- •1. Regular moderate cigarette smokers (minimum 10 cigarettes per day) who want to stop smoking.
- •2. Fagerstrom Nicotine Dependence Rating of 6 or greater.
- •3. Urine cotinine >500 ng/mL.
- •4. Expired air carbon monoxide (CO) > 10 parts per million.
- •5. Healthy males and females 18-65+ years of age.
- •a. If a female subject of child bearing potential, a negative pregnancy test at screening and admission and willing to use an effective method of contraception (unless of non-childbearing potential or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of cytisine.
- •b. If a female subject of non-child bearing potential, a negative pregnancy test at screening and admission. For the purposes of this study, this is defined as the subject being amenorrheic for at least 12 consecutive months or at least 4 months post-surgical sterilisation (including bilateral fallopian tube ligation or bilateral oophorectomy with or without hysterectomy). Menopausal status will be confirmed by demonstrating at screening that levels of follicle stimulating hormone (FSH) fall within the respective pathology reference range. In the event a subject's menopause status has been clearly established (for example, the subject indicates she has been amenorrheic for 10 years), but FSH levels are not consistent with a post-menopausal condition, determination of subject eligibility will be at Investigator's discretion following consultation with the Sponsor.
- •c.If a male subject, willing to use an effective method of contraception (unless anatomically sterile or where abstaining from sexual intercourse is in line with the preferred and usual lifestyle of the subject) from first dose until 3 months after last dose of cytisine.
- •6. Subject with no clinically significant abnormal serum biochemistry, haematology and urine examination values within 28 days before the first dose of cytisine. Subjects on stable medications (e.g. statins, thyroxine, etc) to maintain/control laboratory values are eligible if they meet the above criteria.
- •7. Subject with negative urinary drugs of abuse screen, determined within 28 days before the first dose of cytisine (a positive alcohol result may be repeated at Investigator's discretion).
- •8. Subject with negative human immunodeficiency virus (HIV), hepatitis B surface antigen (Hep B) and hepatitis C virus antibody (Hep C) results.
- •9. Subject with no clinically significant abnormalities in 12-lead ECG determined after minimum of 5 minutes in supine position within 28 days before the first dose of cytisine.
- •10. Subject with no clinically significant abnormalities in vital signs (systolic blood pressure between 90-150 mmHg, diastolic blood pressure (DBP) between 50 and 90 mmHg, and pulse rate (PR) between 40-110 bpm, measured on the dominant arm after minimum of 5 minutes in supine position) determined within 28 days before first dose of cytisine. Subjects taking stable doses of antihypertensives are eligible if their hypertension is well controlled and the above criteria are met.
- •11. Subject must be available to complete the study (including in-clinic stays and post study follow-up) and co
排除标准
- •To be Confirmed at Screening
- •1. Treatment with smoking cessation medications (bupropion, varenicline, any nicotine replacement therapy [NRT]) within 8 weeks of first dose of cytisine.
- •2. Known hypersensitivity/allergy reaction to varenicline, other cytisine-derivatives or any of the excipients in the Tabex formulation (lactose, cellulose, talc, magnesium).
- •3. History of severe hypersensitivity reactions to any other drugs.
- •4. History of any medical condition (e.g. gastrointestinal, renal or hepatic) or surgical condition (e.g. cholecystectomy, gastrectomy) that may affect drug pharmacokinetics (absorption, distribution, metabolism or excretion).
- •5. Difficulty in donating blood on either arm or known history.
- •6. History of alcoholism or drug abuse within last 2 years.
- •7. Use of non-prescription drugs, including vitamins, herbal and dietary supplements within 14 days (or 5 half-lives, whichever is longer) prior to the first dose of cytisine, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety.
- •8. Participated in any investigational drug clinical trial within the previous 3 months or a marketed drug trial within the previous 30 days prior to randomization on Day 1 of Period 1.
- •9. Donation of 450 mL or more blood or had history of significant blood loss due to any reason or had plasmapheresis within 3 months before the first dose of cytisine.
- •10. Inability to communicate well with Investigators (i.e., language problem, poor mental development or impaired cerebral function).
- •11. Any other condition that the Principal Investigator considers making the subject unsuitable for this study.
- •To be Re-Confirmed Prior to Start of Dosing (Day -1):
- •1. Development of any exclusion criteria since screening.
- •2. Use of non-prescription drugs, including vitamins, herbal and dietary supplements since screening, unless in the opinion of the Investigator the medication will not interfere with the study procedures or compromise subject safety.
- •3. Participation in a clinical study since the screening visit.
- •4. Donation of 450 mL or more blood since the screening visit.
研究者
相似试验
已完成
不适用
Pharmacodynamics and pharmacokinetics of P-3074, a new finasteride topical solution, administered at four different dosesAndrogenetic alopeciaISRCTN19708972Polichem SA (Switzerland)32
进行中（未招募）
不适用
The pharmacokinetics of single and multiple doses of intravenous paracetamol in children - Pharmacokinetics of I.V paracetamol in childreThere is no medical condition to be investigated. This is a pharmacokinetic study to be performed in children routinely treated with intravenous paracetamol for post surgical pain in line with local treatment protocol.EUCTR2009-012585-30-GBHS Grampian Research and Development
进行中（未招募）
不适用
The pharmacokinetics of single and multiple doses of intravenous ketorolac in children - Pharmacokinetics of I.V Ketorolac in ChildreThere is no medical condition being investigated. This is a pharmacokinetic study to be performed in children routinely treated with ketorolac for post surgical pain in line with local treatment protocols.EUCTR2009-012512-41-GBHS Grampian
已完成
1 期
Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple MyelomaMultiple MyelomaNCT00080405Millennium Pharmaceuticals, Inc.40
尚未招募
2 期
Multiple-dose pharmacokinetics and ex vivo pharmacodynamics of the fixed-dosed artemisinin based combination therapies (ACTs) of the antimalarial drugs Artequick (artemisinin-piperaquine) and Coarsucam (artesunate-amodiaquine) in healthy male Vietnamese volunteersACTRN12609000846224Australian Department of Defence44